Search by Algolia
Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Oak Valley BancorpOak Valley Bancorp Reports 3.2% Asset Growth, Net Income Decline in 2024
EAGLE FINANCIAL SERVICES INCEagle Financial Services Reports 63.97% Increase in Net Income for Fiscal Year 2024
STRATS SM TRUST FOR U S CELL CORP SEC SERIES 2004 6Synthetic Fixed-Income Securities, Inc. Files 10-K for STRATS Trust for United States Cellular Corporation
DUOS TECHNOLOGIES GROUP, INC.Duos Technologies Reports $7.28 Million Revenue for Fiscal Year 2024, Faces 3% Decline
Expion360 Inc.Expion360 Reports 6% Decrease in Net Sales for Fiscal Year 2024, Despite Q4 Revenue Surge
Velo3D, Inc.Velo3D Reports 47% Revenue Decline and $73.3 Million Net Loss for Fiscal Year 2024
Bluejay Diagnostics, Inc.Bluejay Diagnostics Reports $7.7 Million Net Loss for Fiscal Year 2024
Biomea Fusion, Inc.Biomea Fusion Reports $138.4 Million Net Loss for 2024, Announces Leadership Transition and Strategic Shift
Soluna Holdings, IncSoluna Holdings Reports $63.3M Net Loss and Revenue Growth to $38M in 2024
Dragonfly Energy Holdings Corp.Dragonfly Energy Reports 21.3% Revenue Decline, Faces Financial Challenges
Mitesco, Inc.Mitesco, Inc. Reports $43,700 Revenue for Fiscal Year 2024, Significant Increase from Previous Year
Vivos Therapeutics, Inc.Vivos Therapeutics Reports $15M Revenue for Fiscal Year 2024, Shifts Business Model
EXOZYMES INC.eXoZymes Reports Improved Working Capital and Increased Net Loss in 2024
CHINA PHARMA HOLDINGS, INC.China Pharma Holdings Reports 36% Revenue Decline and Gross Loss for Fiscal Year 2024
Alaunos Therapeutics, Inc.Alaunos Therapeutics Reports $4.7 Million Net Loss for Fiscal Year 2024, Focuses on Obesity Program
Orchestra BioMed Holdings, Inc.Orchestra BioMed Reports $61M Net Loss and 4% Revenue Decline for 2024
Allarity Therapeutics, Inc.Allarity Therapeutics Reports $24.5 Million Net Loss and Strategic Focus on Stenoparib
IO Biotech, Inc.IO Biotech Reports $95.5 Million Net Loss for 2024, Highlights Clinical Trial Progress
AVENUE THERAPEUTICS, INC.Avenue Therapeutics Reports $11.7 Million Net Loss for 2024, Cash Reserves Increase
HealthLynked CorpHealthLynked Corp. Reports 47% Revenue Decline and $6.1 Million Net Loss for Fiscal Year 2024
FORUM MARKETS Inc180 Life Sciences Corp. Reports 69% Improvement in Net Loss for 2024
Sidus Space Inc.Sidus Space Inc. Reports 22% Revenue Decline and Increased Net Loss for Fiscal Year 2024
Rani Therapeutics Holdings, Inc.Rani Therapeutics Reports $56.6M Net Loss for 2024, Improved from Previous Year
Open Lending CorpOpen Lending Corporation Reports 80% Revenue Decline and Significant Losses in 2024 Fiscal Year
Bionano Genomics, Inc.Bionano Genomics Reports $30.7 Million Revenue and $112 Million Net Loss for 2024